Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma

McAleenan, Alexandra; Jones, Hayley E; Kernohan, Ashleigh; Robinson, Tomos; Schmidt, Lena; Dawson, Sarah; Kelly, Claire; Leal, Emmelyn Spencer; Faulkner, Claire; Palmer, Abigail; Wragg, Christopher; Jefferies, Sarah; Brandner, Sebastian; Vale, Luke; Higgins, Julian P T; Kurian, Kathreena M.

doi:10.1002/14651858.cd013387.pub2

Cited by 12 publications

(13 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSENEN expression levels were significantly increased in astrocytomas compared to oligodendrogliomas ( Figures 3A,B ) and further increased along with grade II to III progression ( Figures 3C,E ). IDH mutation and 1p/19q codeletion are unique and are clinically significant molecular features in low-grade gliomas ( Dono et al, 2021 ; McAleenan et al, 2022 ). We, therefore, investigated the relationship between PSENEN expression level and the status of IDH mutation and 1p/19q codeletion.…”

Section: Resultsmentioning

confidence: 99%

“…The clinical analysis showed that PSENEN expression levels were higher in astrocytomas, high-grade tumors, IDH wildtype, and 1p/19q wildtype tumors than in their corresponding phenotype. These clinical features associated with high PSENEN expression levels are all correlated with poor clinical outcomes ( McAleenan et al, 2022 ). Therefore, it was concluded that elevated expression of PSENEN was strongly associated with poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunological and prognostic analysis of PSENEN in low-grade gliomas: An immune infiltration-related prognostic biomarker

Chen

Liang²,

Ma³

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Metformin is widely used in the treatment of type 2 diabetes (T2D) and plays a role in antitumor and antiobesity processes. A recent study identified its direct molecular target, PEN2 (PSENEN). PSENEN is the minimal subunit of the multiprotein complex γ-secretase, which promotes the differentiation of oligodendrocyte progenitors into astrocytes in the central nervous system. This study was mainly based on gene expression data and clinical data from the TCGA and CGGA databases. Analysis of differential expression of PSENEN between tissues from 31 cancers and paracancerous tissues revealed that it had high expression levels in most cancers except 2 cancers. Using univariate Cox regression analysis and Kaplan-Meier survival analysis, a high expression level of PSENEN was shown to be a risk factor in low-grade gliomas (LGG). Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analyses indicated that PSENEN is widely involved in immune-related signaling pathways in LGG. PSENEN expression level was significantly associated with TMB, MSI, tumor stemness index, and the expression levels of immunomodulatory genes in LGG. Finally, immune infiltration analysis revealed that PSENEN level was associated with the presence of various immune infiltrating cells, among which PSENEN was strongly associated with the presence of M2 macrophages and played a synergistic pro-cancer role. In conclusion, PSENEN may partially influence prognosis by modulating immune infiltration in patients with LGG, and PSENEN may be a candidate prognostic biomarker for determining prognosis associated with immune infiltration in LGG.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunological and prognostic analysis of PSENEN in low-grade gliomas: An immune infiltration-related prognostic biomarker

Chen

Liang²,

Ma³

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…The protocol for the review was published in the Cochrane Database of Systematic Reviews [ 20 ], and the review was undertaken and reported following Cochrane's guidance (which is consistent with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses [PRISMA]) [ 21 ]. A more detailed account of the methods and results can be found in the full Cochrane publication [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review

Brandner

McAleenan

Jones

et al. 2022

Neuropathology Appl Neurobio

Self Cite

View full text Add to dashboard Cite

Codeletion of chromosomal arms 1p and 19q, in conjunction with a mutation in the isocitrate dehydrogenase 1 or 2 gene, is the molecular diagnostic criterion for oligodendroglioma, IDH mutant and 1p/19q codeleted. 1p/19q codeletion is a diagnostic marker and allows prognostication and prediction of the best drug response within IDH-mutant tumours. We performed a Cochrane review and simple economic analysis to establish the most sensitive, specific and cost-effective techniques for determining 1p/19q codeletion status. Fluorescent in situ hybridisation (FISH) and polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) test methods were considered as reference standard. Most techniques (FISH, chromogenic in situ hybridisation [CISH], PCR, real-time PCR, multiplex ligation-dependent probe amplification [MLPA], single nucleotide polymorphism [SNP] array, comparative genomic hybridisation [CGH], array CGH, next-generation sequencing [NGS], mass spectrometry and NanoString) showed good sensitivity (few false negatives) for detection of 1p/19q codeletions in glioma, irrespective of whether FISH or PCR-based LOH was used as the reference standard.Both NGS and SNP array had a high specificity (fewer false positives) for 1p/19q codeletion when considered against FISH as the reference standard. Our findings suggest that G banding is not a suitable test for 1p/19q analysis. Within these limits, considering cost per diagnosis and using FISH as a reference, MLPA was marginally more cost-effective than other tests, although these economic analyses were limited by the range of available parameters, time horizon and data from multiple healthcare organisations.

show abstract

“…Figure 2 Data Extraction Table, from Hanna et al [13] Figure 3 Cost Extraction Table, from Hanna et al [13] Figure 4 Example of decision tree model. Figure from McAleenan et al (2022) [17]…”

Section: Declarationsmentioning

confidence: 99%

“…A review to assess diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma was included as part of the programme grant [17]. As such, this review assessed the diagnostic test accuracy (in terms sensitivity and speci city) for each of the tests.…”

Section: Economic Decision Model Case Study -Taken From Mcaleenan Et ...mentioning

confidence: 99%

Incorporating Economic Methods into Cochrane Systematic Reviews: Case Studies in Brain Tumour Research

Kernohan

Robinson

Vale

2023

Preprint

View full text Add to dashboard Cite

Background: Cochrane systematic reviews have established methods for identifying and critically appraising effects evidence in health. In addition to evidence regarding the effects of interventions, the resource implications of such interventions can have a huge impact on decision makers ability to adopt and implement them. We present examples of the three approaches to include economic evidence in Cochrane reviews. Methods: The Cochrane Handbook suggest three different methods of integrating economic evidence into reviews: the Brief Economic Commentary (BEC), the Integrated Full Systematic Review of Economic Evaluations (IFSREE) and using an Economic Decision Model. Using examples from a suite of systematic reviews in brain tumour research, we utilised each method to address three different research questions. A BEC was utilised in a review that evaluates the long-term side effects of radiotherapy (with or without chemotherapy). An IFSREE was utilised in a review assessing different treatment strategies for newly diagnosed glioblastoma in the elderly. Finally, an economic model was included in a review assessing diagnostic test accuracy for tests of codeletion of chromosomal arms in people with glioma Results: The BEC mirrored the results of the main review and found a paucity of quality evidence with regard with regard to side effects of radiotherapy in those with glioma. The IFSREE identified a single economic evaluation regarding glioblastoma in the elderly, but this study had a number of methodological issues. The economic model identified a number of potentially cost-effective strategies for tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Conclusions: There are strengths and limitations of each approach of integrating economic evidence in a Cochrane systematic review. The type of research question, resources available and study timeline should be considered which choosing which approach to use when integrating economic evidence.

show abstract

Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma

Abstract: Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Cited by 12 publications

References 150 publications

Immunological and prognostic analysis of PSENEN in low-grade gliomas: An immune infiltration-related prognostic biomarker

Immunological and prognostic analysis of PSENEN in low-grade gliomas: An immune infiltration-related prognostic biomarker

Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review

Incorporating Economic Methods into Cochrane Systematic Reviews: Case Studies in Brain Tumour Research

Contact Info

Product

Resources

About